AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27488272
Drug: Three-phase multifaceted
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-phase multifaceted intervention including academic detailing with a pharmacist, GP-led medicines reviews, web-based pharmaceutical treatment algorithms, and tailored patient information leaflets
Trial: 27488272
Drug: GP-led medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GP-led medicines reviews with patients present
Trial: 10689295
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nefopam as Acupan(R) administered as a 5‐ or 20‐min intravenous infusion
Trial: 10689295
Drug: Vehicle (control)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (control) administered to subjects during the control phase
Trial: 30121630
Drug: Spironolactone treatment
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone treatment for 9 months
Trial: 30121630
Drug: Spironolactone treatment
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone treatment for 9 months (within-person analysis)
Trial: 25637909
Drug: 10-session individual
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-session individual and group cognitive behavior therapy (CBT) for anxiety disorders
Trial: 19430060
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Iron polymaltose complex (IPC), n=59
Trial: 19430060
Drug: Oral Ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ferrous sulfate (FS), n=59
Trial: 15060518
Drug: L-DOPA (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (200 mg) and benserazide (50 mg) administered 1 hour before sleeping for 30 days
Trial: 9215056
Drug: Topical anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthesia with 0.4% oxybuprocaine
Trial: 27406638
Drug: Cotrimoxazole (CTX)
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (CTX) prophylaxis administered from 6 weeks of age
Trial: 24076367
Drug: Bronchodilator tiotropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator tiotropium (18 mcg)
Trial: 24076367
Drug: Bronchodilator salmeterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator salmeterol (50 mcg)
Trial: 24076367
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (30 mg once daily for 2 weeks)
Trial: 24076367
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (for 2 weeks)
Trial: 24076367
Drug: Post-treatment (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment (4 weeks after cessation of prednisolone)
Trial: 24076367
Drug: Dyspnea VAS
RxNorm normalized name: VP/VA COPOLYMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dyspnea VAS score after 2 weeks of treatment
Trial: 23592936
Drug: FDTV 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDTV 2 mg/180 mg once per day
Trial: 23592936
Drug: T 2
RxNorm normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T 2 mg once per day
Trial: 18417461
Drug: Rimonabant 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 20 mg once daily plus a calorie-restricted diet
Trial: 18417461
Drug: Rimonabant 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 5 mg once daily plus a calorie-restricted diet
Trial: 18417461
Drug: Rimonabant 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 20 mg and 5 mg
Trial: 15917157
Drug: Intranasal 17beta‐oestradiol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 17beta‐oestradiol, 300 microg daily
Trial: 15917157
Drug: Transdermal matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal matrix patch 17beta‐oestradiol, 50 microg/day
Trial: 11029964
Drug: Basal feed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal feed + rapeseed oil (60 g/kg feed)
Trial: 11029964
Drug: Basal feed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal feed + rapeseed oil (60 g/kg feed) + vitamin E (200 mg/kg)
Trial: 24859430
Drug: Regular supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular supervised aquatic exercise (low-intensity aerobic aquatic exercise, twice a week for 10 years)
Trial: 22730113
Drug: Dexamethasone with
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone with thalidomide (200 mg daily) for 12 months
Trial: 12031363
Drug: Adjunctive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive treatment with oral nifedipine and deflazacort
Trial: 9822140
Drug: Combined thiazide
RxNorm normalized name: althiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined thiazide and potassium-sparing diuretic
Trial: 7521907
Drug: Filgrastim (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (both doses combined)
Trial: 31196813
Drug: Solithromycin 1000
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solithromycin 1000 mg (single dose oral)
Trial: 31196813
Drug: Ceftriaxone 500
RxNorm normalized name: ceftriaxone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 500 mg (intramuscular) plus Azithromycin 1000 mg (oral)
Trial: 21130937
Drug: Treatment interventions
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment interventions for complicated grief
Trial: 9184363
Drug: iv meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv meropenem 1 g tds
Trial: 9184363
Drug: iv cefotaxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv cefotaxime 1 g tds and iv metronidazole 500 mg tds
Trial: 1351538
Drug: Prolonged chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged chemotherapy (with tamoxifen for postmenopausal patients)
Trial: 3114351
Drug: Intermittent transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent transdermal nitroglycerin (16 h/day)
Trial: 3114351
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal nitroglycerin (24 h/day)
Trial: 28436092
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (supplement (+) group)
Trial: 28436092
Drug: No creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No creatine supplementation (supplement (-) group)
Trial: 21983766
Drug: nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebivolol 5 mg
Trial: 16931217
Drug: Once-daily sevelamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily sevelamer dosing
Trial: 16931217
Drug: Thrice-daily sevelamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily sevelamer dosing
Trial: 11110230
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg/100 mg
Trial: 11110230
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg/16 mg
Trial: 11110230
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg/50 mg plus HCTZ 12.5 mg
Trial: 11110230
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg plus HCTZ 12.5 mg
Trial: 8882193
Drug: Oral artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral artemether (300 mg) followed by mefloquine (750 mg at 24 h and 500 mg at 30 h)
Trial: 8882193
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate (300 mg) followed by mefloquine (750 mg at 24 h and 500 mg at 30 h)
Trial: 1407887
Drug: Sequential combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combined hormone replacement therapy (various regimens)
Trial: 1407887
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (10 mg)
Trial: 1407887
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (1 mg)
Trial: 4061431
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment with follow-up interviews
Trial: 29781302
Drug: Additional Family-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional Family-Based Treatment (FBT)
Trial: 29781302
Drug: Alternate Treatment
RxNorm normalized name: Target Alternate Site Lancet 26G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate Treatment Group
Trial: 20522617
Drug: Atomoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine treatment after 1 week
Trial: 20522617
Drug: Atomoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine treatment after 2 to 3 weeks
Trial: 9385104
Drug: Proposed tests
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed tests for treatment effect on time to disease under informative censoring assumptions.
Trial: 9385104
Drug: Semiparametric estimators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semiparametric estimators for treatment effect.
Trial: 224125
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate preparation
Trial: 31970563
Drug: 1.23% acidulated
RxNorm normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.23% acidulated fluoride gel and CO2 laser (0.066 J/cm2)
Trial: 24614832
Drug: Microwave diathermy
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microwave diathermy (MD) treatment and exercises
Trial: 22458574
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitors (UFH + GPI)
Trial: 17687635
Drug: High-dose pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pravastatin (40 mg/day)
Trial: 17687635
Drug: Low-dose pravastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose pravastatin (10 mg) + ezetimibe (10 mg)
Trial: 7599345
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g bid sucralfate gel
Trial: 7599345
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g qid sucralfate suspension
Trial: 3334108
Drug: Naproxen 375
RxNorm normalized name: naproxen 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 375 mg twice daily
Trial: 3334108
Drug: Naproxen 750
RxNorm normalized name: naproxen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 750 mg twice daily
Trial: 30775427
Drug: Nebulized glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized glycopyrrolate (GLY) 25 mcg twice daily
Trial: 30775427
Drug: Nebulized glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized glycopyrrolate (GLY) 50 mcg twice daily
Trial: 30775427
Drug: Tiotropium (TIO;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (TIO; 18 mcg once daily)
Trial: 27609033
Drug: sWBV (side-alternating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sWBV (side-alternating whole body vibration) for 14 weeks with ten 9-minute sessions weekly
Trial: 16572920
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg test formulation
Trial: 7914759
Drug: Oral sulphasalazine
RxNorm normalized name: sulfasalazine Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sulphasalazine (2g/day)
Trial: 3053176
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose warfarin (mean daily dose of 4.6 mg)
Trial: 29072166
Drug: Protein rich
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein rich meal during each treatment in the intervention group (IG)
Trial: 23380567
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg daily for 4 weeks
Trial: 23380567
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg daily for 4 weeks
Trial: 20156334
Drug: Phytalgic (food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytalgic (food supplement containing fish oils, urtica dioica, zinc, and vitamin E)
Trial: 10383925
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 500 mg bosentan (3.7 MBq)
Trial: 10383925
Drug: Intravenous dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose of 250 mg bosentan (3.7 MBq)
Trial: 2679831
Drug: diazepam 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 35 mg
Trial: 2679831
Drug: diazepam (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam (both doses)
Trial: 9125
Drug: Oxypertine 20
RxNorm normalized name: oxypertine
DrugBank: Oxypertine (DB13403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxypertine 20 mg orally as a nocturnal sedative and again on the morning of operation
Trial: 9125
Drug: Papaveretum 10
RxNorm normalized name: papaveretum 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaveretum 10 mg
Trial: 31092024
Drug: Epidural oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural oxycodone (EPI group; n = 18)
Trial: 31092024
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone (IV group; n = 12)
Trial: 28692172
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 100,000 IU monthly
Trial: 28692172
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 100,000 IU monthly (with baseline 25-hydroxyvitamin D ≤ 30 nmol L-1)
Trial: 28692172
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 100,000 IU monthly (with baseline 25-hydroxyvitamin D > 30 nmol L-1)
Trial: 8470626
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole plus 4 x 500 mg amoxicillin suspension for 1 wk (group I, n = 35)
Trial: 8470626
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 40 mg omeprazole plus 4 x 500 mg amoxicillin for 1 wk (group II, n = 50)
Trial: 8470626
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 20 mg omeprazole plus 4 x 500 mg amoxicillin for 2 wk (group III, n = 62)
Trial: 8470626
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 20 mg omeprazole (day 1‐14) and 4 x 500 mg amoxicillin (day 8‐14) (group IV, n = 22)
Trial: 8470626
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 20 mg omeprazole for 2 wk (group V, n = 11)
Trial: 3512149
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nalbuphine
Trial: 3512149
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nalbuphine and acetaminophen
Trial: 26967465
Drug: Low-magnitude, high-frequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-magnitude, high-frequency mechanical stimulation (0.3 g; 32-37 Hz) for 2 sessions lasting 10 minutes each, 7 days per week for 1 year.
Trial: 24973176
Drug: Esophageal capsule
RxNorm normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esophageal capsule esophagoscopy (ECE)
Trial: 22616061
Drug: Multiple zygomatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple zygomatic implants (Zyg); 28 zygomatic and 5 standard implants placed.
Trial: 22616061
Drug: Standard implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard implants (Stand); 41 standard implants placed, 3 lost.
Trial: 18328120
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg/HCTZ 12.5 mg
Trial: 10584979
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg omeprazole
Trial: 1862209
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of fluphenazine decanoate (5 to 10 mg every 2 weeks)
Trial: 6352658
Drug: Ceftazidime 0.5
RxNorm normalized name: avibactam-ceftazidime 0.5 g-2 g intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 0.5 g every 12 h for 7 to 10 days
Trial: 6352658
Drug: Tobramycin 1
RxNorm normalized name: tobramycin 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin 1 mg/kg every 8 h for 7 to 10 days
Trial: 24962473
Drug: Macitentan 30
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan 30 mg loading dose on day 1 followed by 10 mg once daily for 3 days
Trial: 24962473
Drug: Sildenafil 20
RxNorm normalized name: sildenafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 20 mg three times a day for 3 days and a single 20 mg dose on day 4
Trial: 21350044
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg oral nicotine lozenge
Trial: 17333521
Drug: Extended-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxybutynin 10 mg once daily
Trial: 17333521
Drug: Extended-release tolterodine
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tolterodine 4 mg once daily
Trial: 17333521
Drug: Immediate-release tolterodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tolterodine 2 mg twice daily
Trial: 15554600
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg for six months
Trial: 9389845
Drug: 4% mepivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% mepivacaine 80 mg
Trial: 9389845
Drug: hyperbaric 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric 0.5% bupivacaine 10 mg
Trial: 25546420
Drug: MABGEL (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MABGEL (2.5 g of gel daily for 12 days containing 10 or 20 mg/g of each mAb)
Trial: 20420544
Drug: Adjuvant medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant medications (tricyclics and antiseizure)
Trial: 7675045
Drug: Gluten-free diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten-free diet with oats (50 to 70 g per day from three sources: two types of wheat-starch flour mixed with oats, muesli containing 60% oats, rolled-oat breakfast cereal)
Trial: 2301781
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (atropine sulfate and isoetharine)
Trial: 7008147
Drug: Diazepam as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam as pre-medication
Trial: 30681185
Drug: Teprenone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprenone (150 mg/day) with long-term low-dose aspirin
Trial: 30681185
Drug: Teprenone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprenone (150 mg/day) with other NSAIDs
Trial: 19034732
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (IMN) (40 mg)